|
REFERENCES
Sequential Versus Concomitant Administration
of Ribavirin and Interferon Alfa-n3 in Patients With Chronic
Hepatitis C Not Responding to Interferon Alone: Results of a
Randomized, Controlled Trial
1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral
hepatitis. N Engl J Med 1997; 336: 347-356[Medline].
2. Carreno V, Marriot E, Quiroga JA. Other approaches to the
treatment of chronic viral hepatitis. J Hepatol 1993; 17(suppl. 1):
127-129[Medline].
3. Marcellin P, Pouteau M, Boyer N, Castelnau C, Erlinger S,
Benhamou JP. Retreatment with recombinant interferon-alfa in
patients with chronic hepatitis C. J Infect Dis 1993; 167:
780-781[Abstract].
4.National Institutes of Health Consensus Development Conference
Panel Statement. Management of hepatitis C. HEPATOLOGY 1997;
26(suppl. 1): 25-105[Medline].
5. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C,
Miglioli M, Barbara L. A pilot study of combination therapy with
ribavirin plus interferon-alfa for interferon-alfa-resistant
chronic hepatitis C. Gastroenterology 1994; 107:
812-817[Medline].
6. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined
treatment with interferon-alfa-2b and ribavirin for chronic
hepatitis C in patients with a previous non-response or
non-sustained response to interferon alone. J Med Virol 1995; 46:
43-47[Medline].
7. Brillanti S, Miglioli M, Barbara L. Combination antiviral
therapy with ribavirin and interferon alfa in interferon alfa
relapsers and non-responders: Italian experience. J Hepatol 1995;
23(suppl. 2): 13-16[Medline].
8. Scharvcz R, Ando Y, Sonnerborg A, Weiland O. Combination
treatment with interferon alfa-2b and ribavirin for chronic
hepatitis C in patients who have failed to achieve sustained
response to interferon alone: Swedish experience. J Hepatol 1995;
23(suppl. 2): 17-21[Medline].
9. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT,
Weiland O, Cavalletto L, et al. Ribavirin enhances the efficacy but
not the adverse effects of interferon in chronic hepatitis C. J
Hepatol 1997; 26: 961-966[Medline].
10. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat
F, Denk H, et al. Histological grading and staging of chronic
hepatitis. J Hepatol 1995; 22: 696-699[Medline].
11. Shindo M, Di Bisceglie AM, Cheung L, Shih JWK, Cristiano K,
Feinstone FM, Hoofnagle JH. Decrease in serum hepatitis C viral RNA
during alpha-IFN therapy for chronic hepatitis C. Ann Intern Med
1991; 115: 700-704[Medline].
12. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin
treatment for chronic hepatitis C. Lancet 1991; 337: 1058-1061.
13. Di Bisceglie AM, Shindo M, Fong T-L, Fried MW, Swain MG,
Bergasa NV, Axiotis CA, et al. A pilot study of ribavirin therapy
for chronic hepatitis C. HEPATOLOGY 1992; 16: 649-654[Medline].
14. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A,
Rassam S, et al. Ribavirin treatment for patients with chronic
hepatitis C: results of a placebo-controlled study. J Hepatol 1996;
25: 591-598.
15. Scotto G, Fazio V, Tantimonaco G. Pilot study of a short
course of ribavirin and alpha interferon in the treatment of
chronic active hepatitis C not responding to alpha-interferon
alone. Ital J Gastroenterol 1996; 28: 505-511.
16. Andreone P, Cursaro C, Gramenzi A, Sbolli G, Fiorino S, Di
Giammarino L, Miniero R, et al. IFN alfa-n3 vs IFN alfa-n3 plus
ribavirin in chronic hepatitis C (CHC) resistant to other IFN alfa
treatments:results of a randomized multicenter trial [Abstract].
HEPATOLOGY 1997; 26: 216A.
17. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso
P, Alberti A. The effect of interferon alfa and ribavirin
combination therapy in naïve patients with chronic hepatitis
C. J Hepatol 1995; 23(suppl. 2): 8-12.
18Koskinas J, Tibbs C, Saleh MG, Pereira LM, McFarlane IG,
Williams R. Effects of ribavirin on intrahepatic and extrahepatic
expression of hepatitis C virus in interferon nonresponsive
patients. J Med Virol 1995; 45: 29-34.
19. Ning Q, Brown D, Parodo J, Cattral M, Fung L, Liu M,
Rotstein O, et al. Ribavirin inhibits viral induced macrophage
production of tumor necrosis factor, interleukin 1 and procoagulant
activity and preserves Th 1 cytokine production, but inhibits Th 2
cytokine response [Abstract]. HEPATOLOGY 1996; 24: 355A.
Return To Article
Copyright © 1998 by the American Association for the Study
of Liver Diseases
|
